Log in

Bioverativ Stock Price, News & Analysis (NASDAQ:BIVV)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range
$104.98
MA: $104.98
$104.98
52-Week Range N/A
VolumeN/A
Average Volume3.03 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.


Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) issued its quarterly earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.25. The biotechnology company had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. The company's revenue was up 27.2% compared to the same quarter last year. View Bioverativ's Earnings History.

Has Bioverativ been receiving favorable news coverage?

News articles about BIVV stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bioverativ earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Bioverativ.

What other stocks do shareholders of Bioverativ own?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:
  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

What is Bioverativ's official website?

The official website for Bioverativ is http://www.bioverativ.com/.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]


MarketBeat Community Rating for Bioverativ (NASDAQ BIVV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe BIVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel